Dermatology company Leo Pharma has entered a strategic technology partnership with software company Veeva Systems for patient-centric digital trials.
A provider of Cloud software for the life sciences industry, Veeva Systems will help Leo Pharma to digitalise its clinical trials.
The latest move builds on the successful integration of the Veeva Clinical Operations Suite.
Through this collaboration, LEO Pharma will use Veeva clinical products that include CDMS, eConsent, eTMF, CTMS, Site Connect, ePRO, Virtual Visits, and eSource.
Using these products, the company will complete its standardisation on existing Veeva clinical technology and be an early adopter of Veeva solutions.
Veeva CEO and founder Peter Gassner said: “We intend to help move the industry forward with a scalable digital trials platform that significantly improves the clinical trial process for patients, sites, and sponsors.”
LEO Pharma intends to obtain higher accuracy in clinical data, significantly improve patient experience and increase patient diversity by adopting the technology and optimised business processes.
It also plans to reduce clinical trial costs and time by 25%.
LEO Pharma Research and Development executive vice-president and head Jörg Möller said: “We’ve been exploring ways to transform clinical trials, but Covid-19 sped up this process. By promptly responding to changing market dynamics, we kept our trials going without delay.
“Partnering with Veeva supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business.”
In April 2021, Parexel and Veeva Systems announced plans to accelerate clinical trials through technology and process innovation, as part of a strategic collaboration.